Rep. Maria Elvira Salazar Buys Biogen Inc. (NASDAQ:BIIB) Shares

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Biogen stock on May 11th. The trade occurred in the Representative’s “UBS BROKERAGE ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 5/29/2026.
• Purchased $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 5/21/2026.
• Purchased $15,001 – $50,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
• Purchased $1,001 – $15,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
• Purchased $15,001 – $50,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
• Purchased $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
• Sold $1,001 – $15,000 in shares of Sherwin-Williams (NYSE:SHW) on 5/12/2026.
• Purchased $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 5/12/2026.
• Purchased $50,001 – $100,000 in shares of Biogen (NASDAQ:BIIB) on 5/11/2026.
• Sold $1,001 – $15,000 in shares of Whirlpool (NYSE:WHR) on 5/11/2026.

Biogen Trading Up 2.3%

Shares of BIIB traded up $4.46 on Thursday, reaching $198.70. 112,640 shares of the company’s stock were exchanged, compared to its average volume of 1,253,917. The business has a 50 day moving average price of $188.07 and a two-hundred day moving average price of $184.03. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 12 month low of $121.05 and a 12 month high of $205.97. The stock has a market capitalization of $29.34 billion, a P/E ratio of 21.31 and a beta of 0.20.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Research analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on BIIB shares. HC Wainwright reissued a “buy” rating on shares of Biogen in a report on Thursday, May 14th. Freedom Capital raised shares of Biogen from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st. The Goldman Sachs Group raised their target price on Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a report on Friday, April 24th. Needham & Company LLC raised Biogen from a “hold” rating to a “buy” rating and set a $255.00 price target for the company in a report on Monday. Finally, Sanford C. Bernstein dropped their price objective on Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Biogen currently has a consensus rating of “Moderate Buy” and a consensus target price of $217.26.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Parallel Advisors LLC boosted its position in shares of Biogen by 1.5% during the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after purchasing an additional 65 shares in the last quarter. Caerus Investment Advisors LLC boosted its position in Biogen by 5.0% during the first quarter. Caerus Investment Advisors LLC now owns 2,801 shares of the biotechnology company’s stock worth $514,000 after purchasing an additional 134 shares during the period. Financial Solutions Advisory Group Inc. purchased a new position in shares of Biogen in the 1st quarter worth about $252,000. Glenmede Trust Co. NA grew its position in Biogen by 17.5% during the first quarter. Glenmede Trust Co. NA now owns 11,652 shares of the biotechnology company’s stock valued at $2,136,000 after acquiring an additional 1,733 shares during the last quarter. Finally, Groupama Asset Managment raised its stake in shares of Biogen by 3.8% during the first quarter. Groupama Asset Managment now owns 8,753 shares of the biotechnology company’s stock worth $1,605,000 after acquiring an additional 322 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.